This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Benign prostatic enlargement (BPE)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Benign prostatic hyperplasia (BPH) is a histological diagnosis characterised by non-malignant proliferative process of the prostatic stromal cells.

  • is considered as the commonest benign neoplasm in males
  • commonly seen in older men and may even be regarded as a natural part of ageing.
  • it is unusual before 50 years of age (2).

Transition zone of the prostrate is affected by BPH which results in compression of the prostatic urethra and restriction of flow out of the bladder.

Benign prostatic obstruction (BPO) is a main aetiology for aging men to experience LUTS and it differs from benign prostatic hyperplasia (BPH) and benign prostatice nlargement (BPE)

BPE refers to an increase in volume of theprostate due to BPH. BPO is an obstruction that results from BPE,which can be confirmed by pressure flow studies, or be highlysuspected from flow rates and if the gland is enlarged (3).

Many patients are asymptomatic or have mild disease. Only 20% of those over 60 years have disease sufficiently severe to warrant surgery.

The cause of the hyperplasia is uncertain. Hormonal and neoplastic explanations have been proposed. The condition is not thought to be premalignant.

BPH Chapter contributor (23/12/18):

  • Maya Anatoly Harris
  • Consultant Urologist at South Warwickshire NHS Foundation Trust


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.